Feasibility and Oncological Safety of Axillary Reverse Mapping in Patients With Locally Advanced Breast Cancer and Partial Response After Neoadjuvant Chemotherapy

Pellicciaro, Marco; Materazzo, Marco; Buonomo, Chiara; Vanni, Gianluca

doi:10.21873/invivo.12529

Cited by 4 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients were assessed for treatment at the BCCA oncology assessment (including history, clinical examination, mammography, chest CT, laboratory examination, hepatobiliary, splenopancreatic ultrasound, and lung function) [ 8 ]. According to the AJCC classifications (8th edition), LABC is a category of breast cancer that includes T3, T4, any N2, or any N3 cases in TNM stage, from stage IIB to IIIC (including inflammatory breast cancer with no distant metastasis) [ 9 ]. Patients with inflammatory breast cancer, recurrence after breast-conserving surgery, and palliative care intentions were included.…”

Section: Methodsmentioning

confidence: 99%

Latissimus dorsi myocutaneous flap repair is effective after neoadjuvant chemotherapy for locally advanced breast cancer

Yang

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

Objective To describe the clinical outcome and physical condition of patients with locally advanced breast cancer (LABC) who received neoadjuvant chemotherapy followed by mastectomy and latissimus dorsi myocutaneous flap repair. Methods A retrospective review of 142 patients with locally advanced breast cancer was selected from 1156 breast cancer patients in the South and North areas of The Affiliated Calmette Hospital of Kunming Medical University between May 2008 and December 2018. Results All participants (n = 142) were women aged 40–55 years (average age 47.35 ± 0.43 years) who received neoadjuvant chemotherapy followed by mastectomy and latissimus dorsi flap repair. The median follow-up period was 16 months (range 12–24 months). For stage of disease, there were 19 cases (13%) in stage IIB, 31 cases (22%) in stage IIIA, 39 cases (28%) in stage IIIB, and 53 cases (37%) in stage IIIC, which were statistically significant with the physical condition of patients (≤ 0.001). Neoadjuvant chemotherapy was administered to shrink the tumors, and an average tumor size decrease from 10.05 ± 1.59 cm × (8.07 ± 1.54) cm to 6.11 ± 1.72 cm × (3.91 ± 1.52) cm (P < 0.001) was considered statistically significant. A t test was used for the ECOG score statistics, and the results showed that the scores were statistically significant (≤ 0.001) before and after neoadjuvant chemotherapy and after surgery. Conclusions Neoadjuvant chemotherapy is an accepted treatment option for patients with locally advanced breast cancer, and the use of a latissimus dorsi musculocutaneous flap for post-mastectomy reconstruction may improve the patients’ physical condition. Our results indicated that this strategy was safe and feasible.

show abstract

Section: Methodsmentioning

confidence: 99%

Latissimus dorsi myocutaneous flap repair is effective after neoadjuvant chemotherapy for locally advanced breast cancer

Yang

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…In recent years, although important progress has been made in the treatment of breast cancer in the areas of surgery, radiotherapy, chemotherapy, and endocrine and targeted therapies, the prognosis of patients has not significantly improved. The molecular mechanisms of the occurrence and development of breast cancer need to be assessed further ( 3 , 4 ). Studies have confirmed that drugs play an important role in the progression of breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Dexmetomidine promotes the activity of breast cancer cells through miR-199a/HIF-1α axis

Wen¹,

Xin²

2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background Breast cancer, as one of the most common malignant tumors in women, is still a great threat to women all over the world. Dexmetomidine (DMED) is a highly selective α2-adrenergic receptor agonist, which has attracted much attention in recent years. This study aimed to clarify the potential mechanism of DMED in regulating the activity of breast cancer cells. Methods Breast cancer cell lines MCF-7 and MDA-MB-231 were treated with DMED. The levels of miR-199a and HIF-1α mRNA were detected using quantitative real-time polymerase chain reaction (QRT-PCR); the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and transwell assays were applied to monitor the activity of breast cancer cells; the apoptosis of breast cancer cells was detected using the caspase-3 activity assay and flow cytometry; binding of miR-199a and HIF-1α was assessed using double luciferase reporter gene assay, and western blot was employed to monitor the level of HIF-1α in cells. Results The cytotoxicity and apoptosis of MCF-7 and MDA-MB-231 cells was inhibited by DMED. It also downregulated the expression of miR-199a in breast cancer cells and enhanced the downregulation of miR-199a to promote the activity of breast cancer cells and inhibit apoptosis. Also, miR-199a targeted HIF-1α. Further functional experiments confirmed that DMED promoted the progression of breast cancer through the miR-199a/HIF-1α axis. Conclusions DMED promotes the activity of breast cancer cells through miR-199a/HIF-1αaxis. This can provide some reference for DMED in the clinical treatment of breast cancer.

show abstract

Antineoplastics

2021

Reactions Weekly

View full text Add to dashboard Cite

Myelotoxicity: case reportA 52-year-old woman developed myelotoxicity during treatment with cyclophosphamide, doxorubicin, carboplatin and paclitaxel for locally-advanced breast cancer (LABC).The woman presented for evaluation of a new onset of palpable breast lesions. Her medical history included renal artery aneurysm treated with covered stents. Subsequent examinations showed triple-negative invasive ductal carcinoma with involvement of axillary lymph node. Based on the examinations, she was diagnosed with LABC. Following consultation with multidisciplinary team, she started receiving neoadjuvant chemotherapy (NAC) with doxorubicin [Adriamycin] and cyclophosphamide scheduled for four cycles followed by carboplatin and paclitaxel scheduled for six cycles [routes and dosages not stated]. However, she developed grade 4 myelotoxicity secondary to neoadjuvant chemotherapy.The woman's treatment cyclophosphamide, doxorubicin, carboplatin and paclitaxel was therefore discontinued after five months. A bilateral breast ultrasonography showed a partial pathological response of neoadjuvant chemotherapy. Thereafter, she was scheduled to undergo axillary lymph-node dissection with fluorescence axillary reverse mapping (ARM). Following injection of fluorescence indocyanine green (ICG), two lymph-nodes draining the ipsilateral upper arm were identified. Thereafter, she underwent axillary lymph-node dissection. Pathological examination confirmed the presence of malignancy in both lymph nodes. Then, right simplex mastectomy followed by placement of a tissue expander was performed. At 1-month follow-up, she was free from distant and loco-regional neoplastic recurrence [outcome of ADR not stated].

show abstract

Feasibility and Oncological Safety of Axillary Reverse Mapping in Patients With Locally Advanced Breast Cancer and Partial Response After Neoadjuvant Chemotherapy

Cited by 4 publications

References 35 publications

Latissimus dorsi myocutaneous flap repair is effective after neoadjuvant chemotherapy for locally advanced breast cancer

Latissimus dorsi myocutaneous flap repair is effective after neoadjuvant chemotherapy for locally advanced breast cancer

Dexmetomidine promotes the activity of breast cancer cells through miR-199a/HIF-1α axis

Antineoplastics

Contact Info

Product

Resources

About